Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity.
Statin use can be accompanied by a variety of musculoskeletal complaints. The authors describe the clinical characteristics of case patients who experienced adverse statin-induced musculoskeletal symptoms within a large population-based cohort in Central Wisconsin. Case status was determined based on elevated serum creatine kinase (CK) levels and the presence of at least 1 physician note reflecting an increased index of suspicion for statin intolerance. From the medical records of nearly 2 million unique patients, the authors identified more than 20,000 potential study patients ( approximately 1%) having CK data and at least 1 exposure to a statin drug. Manual screening was completed on 2227 patients with CK levels in the upper 10th percentile. Of those screened, 267 met inclusion criteria (12.0% eligibility) and 218 agreed to participate in a retrospective study characterizing the risk determinants of statin-induced muscle toxicity. Three categoric pain variables were graded retrospectively (distribution, location, and severity of pain). The presenting complaints of the case patients were extremely heterogeneous. The number of patients with a compelling pain syndrome (diffuse, proximal muscle pain of high intensity) increased at higher serum CK levels; the number of patients with indeterminate pain variables decreased at higher serum CK levels. The lines reflecting these relationships cross at a CK level of approximately 1175 U/L, approximately half the threshold level needed to make a clinical diagnosis of "myopathy" (ie, CK >10-fold the upper limit of normal).
Mareedu
Ravi K
RK
Department of Internal Medicine, Marshfield Clinic, Marshfield, WI, USA.
Modhia
Falgun M
FM
Kanin
Elenita I
EI
Linneman
James G
JG
Kitchner
Terrie
T
McCarty
Catherine A
CA
Krauss
Ronald M
RM
Wilke
Russell A
RA
D003402:Creatine Kinase / Q000097:blood / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D015994:Incidence; D016347:Medical Records Systems, Computerized / Q000706:statistics & numerical data*; D009135:Muscular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D003402:Creatine Kinase